BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

Phase III results put obinutuzumab in line for approval ...

Regulatory B cells (Breg) have emerged as pivotal modulators of the immune system, mediating immune tolerance and preventing excessive inflammatory responses. These specialised B cells exert their ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout ...

Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, immunotherapy is referred to treating cancer. As tumors progress, they secrete ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...